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Abstract: Lynch syndrome (LS) is the most common form of inherited predisposition to develop cancer mainly in the co-
lon and endometrium but also in other organ sites. Germline mutations in DNA mismatch repair (MMR) gene cause the 
transmission of the syndrome in an autosomal dominant manner. The management of LS patients is complicated by the 
large variation in age at cancer diagnosis which requires these patients to be enrolled in surveillance protocol starting as 
early as in their second decade of life. Several environmental and genetic factors have been proposed to explain this phe-
notypic heterogeneity, but the molecular mechanisms remain unknown. Although the presence of genetic anticipation in 
Lynch syndrome has been suspected since 15 years, only recently the phenomenon has been increasingly reported to be 
present in different cancer genetic syndromes including LS. While the biological basis of earlier cancer onset in succes-
sive generations remains poorly known, recent findings point to telomere dynamics as a mechanism significantly contrib-
uting to genetic anticipation in Lynch syndrome and in other familial cancers. In this review, we summarize the clinical 
and molecular features of Lynch syndrome, with a particular focus on the latest studies that have investigated the molecu-
lar mechanisms of genetic anticipation. 
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INTRODUCTION 
  Lynch syndrome (LS), also known as hereditary non-
polyposis colorectal cancer (HNPCC), is a cancer predispos-
ing syndrome characterized by autosomal dominant inheri-
tance of a germline mutation in the DNA mismatch repair 
genes. This syndrome represents the most common heredi-
tary form of colorectal cancer (CRC), accounting for 2-4% 
of the annual worldwide incidence [1]. Individuals with LS 
develop tumors at an early age, often <45 years. The vast 
majority of the mutations is highly penetrant, therefore mul-
tiple generations in the same family are affected by cancer 
and skipping of a generation is a rare event [2]. Individuals 
affected by LS are also predisposed to various types of ex-
tracolonic cancers mainly in the endometrium, stomach, 
ovary, hepatobiliary tract, upper urinary tract, small bowel, 
brain and pancreas [3]. There are conflicting evidences of a 
higher risk of breast and prostate cancers associated with the 
syndrome [4,5]. The lifetime risk of cancer development 
depends on patients’ sex and the MMR-gene involved. In 
mutation carriers, the lifetime CRC risk is estimated to be 
50-80% [6]. In women the higher risk is for endometrial 
cancer, which is estimated to be 40-60%, with LS being di-
agnosed in approximately 2% of all endometrial cancer pa-
tients [7]. The risk for other extra-colonic cancers associated 
with MMR genes mutations is cumulatively less than 10% 
[8], and these cancers are more frequently associated to 
MSH2 mutations [9,10]. In LS, CRCs are typically located in 
the proximal colon (two-thirds of cases) and patients present  
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a high frequency of multiple tumors, either synchronous or 
metachronous (35% of patients) [2]. LS tumors are also less 
likely to metastasize than sporadic ones [11,12]. 
MMR GENES, MSI AND TUMORIGENESIS 
  Most of the disease causing mutations in LS fall in one of 
four genes all involved in the DNA-mismatch repair system 
(MMR): MSH2, MLH1, MSH6 and PMS2 [13]. MMR genes 
encode for proteins involved in the identification and repair 
of replication errors, such as mispaired nucleotides or small 
insertion/deletion loops (IDLs), caused by the slippage of 
DNA polymerase while replicating DNA regions containing 
short tandem repeats (STRs) also known as microsatellite 
loci. In eukaryotes the mismatch repair requires the presence 
of two heterodimeric complexes called MutS and MutL. In 
mammalian cells, the MutS heterodimer recognizes replica-
tion errors in the form of mismatches, and recruits MutL to 
the site of damage. MutS, formed by MSH2-MSH6, recog-
nizes single base mismatches or insertion/deletion loops, 
while the MutS complex, made by MSH2-MSH3, is re-
sponsible for the recognition of IDLs of 2 to 8 nucleotides. 
The MutL heterodimer, consisting of MLH1 and PMS2, 
forms a ternary complex with one of the MutS complexes 
bound to the mismatch site, and together with ExoI, PCNA 
(Proliferating Cell Nuclear Antigen) and DNA polymerase, 
leads to strand discrimination, error removal and DNA re-
synthesis [14].  
  So far, LS has been associated with mutations in seven 
different genes: MLH1, MSH2, MSH6, PMS1, PMS2, 
MLH3 and EXO1 [15]. More recently, germline deletions of 
the EpCAM gene (epithelial cell adhesion molecule, for-
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LS families/cases and are recognized as a novel class of mu-
tations predisposing to LS [16]. Despite the increasing sensi-
tivity of mutation screening techniques in candidate genes, in 
a subset of families fulfilling Amsterdam I or II criteria (40-
70%) an MMR gene defect has not been identified yet 
[17,18]. These families have been referred since then as fa-
milial colorectal cancer type X [19], and are characterized by 
MSS tumors, lower cancer risk and later onset of CRC (10 
years after the median age of onset in LS), and a minor risk 
of extracolonic cancers compared to both MSH2 and MSH6 
mutation carriers. The molecular genetics of familial colo-
rectal cancer type X is still unknown but new techniques, 
such as Next Generation Sequencing (NGS) technology, 
appear to be a promising tool in identifying gene mutations 
and/or a combination of genetic variants associated with 
cancer predisposition in this subgroup of families. In fact, 
the possibility to rapidly produce an enormous volume of 
data cheaply, makes feasible the simultaneous screening of 
several candidate genes including regions non-traditionally 
target of mutations (such as introns and untranslated re-
gions). Novel specialized platforms based on NGS are ap-
parently ready to hit the market and to revolutionize MMR 
genes mutation screening, as it was the case for Multiplex 
Ligation Probe Amplification (MLPA). 
  Indeed, MLPA analysis turned out to be extremely useful 
in identifying genomic rearrangements in MMR genes which 
account for nearly 30% of all germline mutations identified 
so far, including germline deletions in the EpCAM gene. In 
LS patients harboring a germline mutation, somatic loss or 
inactivation of the wild-type allele, through point mutations, 
methylation, gene conversion or LOH, results in a general-
ized genomic instability recognized as the accumulation, 
with high frequency, of mutations in these STR sequences 
known as microsatellite instability (MSI). MSI is the hall-
mark of LS and the presence of high levels of instability 
(MSI-H) in a tumor tissue proves the association of cancer 
with the syndrome. As a consequence, MSI testing is highly 
recommended whenever a patient is suspected of having LS. 
  In 1997, the National Cancer Institute proposed a panel 
of 5 microsatellites, known as the Bethesda panel [20], to 
test the MSI status and classify tumors in three main catego-
ries: tumors that do not show MSI termed microsatellite sta-
ble (MSS); tumors showing a low level of instability (MSI-L 
which is generally considered the presence of single altered 
microsatellite marker in the Bethesda panel of five loci or up 
to two in an extended panel of ten); and tumors MSI-H with 
instability in more than 20% of the microsatellite marker loci 
analyzed. MSI-L tumors, with instability mostly limited to 
mononucleotides repeats, have been frequently but not ex-
clusively associated with mutations in the MSH6 gene 
[21,22]. In many cases, tumors with low-level of microsatel-
lite instability are biologically and histologically similar to 
the MSS ones although the use of expanded panel of mono-
nucleotide markers has been recently demonstrated effective 
in reclassifying the majority of MSI-L cases as either MSI-H 
or MSS [23-27]. Because mononucleotide markers allow a 
more accurate assessment of MSI [28,29], using these mark-
ers the sensitivity and specificity for detection of MSI 
reached nearly 100% [29]. While the MSS category is 
largely prevalent in sporadic cancers, the MSI-H status has 
been identified in up to 15-20% of all CRCs, most of which 
are sporadic. A genetic predisposition causing high levels of 
instability has been identified only in 1-4% of MSI-H CRCs 
and after the identification of a germline mutation in one of 
the MMR genes the Lynch syndrome is diagnosed. In spo-
radic MSI-H tumors the presence of instability is generally 
caused by the silencing of the MLH1 gene through the so-
matic hypermethylation of its promoter, which leads to the 
complete loss of the MLH1 protein. The presence of the 
BRAF V600E mutation in MSI-H, MLH1-negative CRCs, is 
a highly specific marker for the sporadic origin of the cancer 
[30,31]. On the contrary, mutations in the beta-catenin, 
mainly in exon 3, have been observed only in MSI-H tumor 
of patients with LS [32]. 
  The “mutator phenotype”, caused by the inactivation of 
the MMR system, is also characterized by the accumulation 
of mutations in different target genes containing ho-
mopolymeric runs of a single nucleotide. The first of these 
target genes was identified almost two decades ago when, in 
90% of the MSI-H CRCs analyzed, a mutation in a stretch of 
ten consecutive As in the coding sequence of TGFbR2 was 
found [33]. Since then, many other target genes sharing the 
presence of short repeat regions in their coding sequence, 
have been identified and all of them are inactivated by 
frameshift mutations in a context of MMR deficiency [34]. 
Among these MSI target genes the large majority encodes 
for proteins active in pathways of fundamental importance 
for cell homeostasis such as cell proliferation, cell signaling, 
cell cycle, apoptosis and DNA repair. Mutations in these 
genes usually confer a selectable growth advantage to the 
cells driving the consequent malignant transformation [35]. 
Interestingly, all human MMR genes, except MLH1, present 
a polyA repeat in their own coding sequence suggesting that 
MMR system could gradually lose other components in a 
context of wide genomic instability. However, the identity of 
the mutated genes with a functional role in the tumor pro-
gression and those that simply represent bystander markers 
of MSI is not clear yet [36].  
  Although many evidences support the concept that insta-
bility caused by MMR deficiency plays a causative role in 
cancer development, it is likely that the microenvironment of 
the colon and other cancer sites may contribute to tumor pro-
gression and the eventual metastatic process [37]. 
  In Lynch patients the adenoma-carcinoma sequence is 
accelerated compared to sporadic CRCs. In fact, the progres-
sion from adenoma to carcinoma in these patients may take 
less than 2-3 years compared to 8-10 years observed in spo-
radic CRC [38]. Adenomas identified in Lynch syndrome 
patients show peculiar histological features, including a high 
degree of dysplasia and villous architecture, which are nor-
mally related with a more pronounced risk of malignant de-
generation. Considering the histologic features and the ac-
celerated progression one would expect a worse prognosis 
for Lynch patients’ tumors, which is not the case. In contrast, 
MSI tumors (both LS-related and the MSI-H sporadic) are 
characterized by a better prognosis compared to MSS spo-
radic tumors, when controlled for age and stage [39]. Simi-
larly, LS-associated tumors, are also histologically well de-
fined: colorectal cancers are diploid, poorly differentiated, 
mucinous and present a higher frequency of Crohn’s like 
reaction and tumor-infiltrating lymphocytes [40]. As previ-Anticipation in Lynch Syndrome  Current Genomics, 2011, Vol. 12, No. 7    453 
ously mentioned, while all these features are usually indica-
tive of a worse prognosis, Lynch patients do survive longer 
than patients affected by sporadic CRC [41]. In one of the 
largest studies performed so far on healthy mutation carriers, 
intensive surveillance and satisfying follow-up compliance 
contributed to unincreased mortality despite an observed 
higher cancer risk when compared to non carriers [42]. Thus, 
the increased surveillance and the intrinsic biological fea-
tures of LS tumors combine to reduce cancer-related morbid-
ity and mortality [12]. These findings in combination with 
the presence of multiple primary extracolonic tumors, and 
with the observed lower frequency of metastases, led to the 
hypothesis that Lynch patients develop significant defenses 
against cancer through an enhanced immune response [43]. 
Both the infiltration of T lymphocytes (TILs) in the tumor 
and the presence of genomic instability that could reduce 
tumor vitality have been proposed to explain the better prog-
nosis of LS-associated tumors [44]. The lack of mismatch 
repair has been shown to generate in MSI-H tumors new 
immunogenic frameshift peptides (FSPs) that elicit an anti-
tumor inflammatory response mediated by CD8+ T cells able 
to kill tumor cells through a cytotoxic mechanism [45]. Al-
though  2-microglobulin (2M) mutations leading to the 
loss of MHC class I antigen presentation to CD8+ T cells 
have been documented in LS patients [46], no grade IV me-
tastatic MSI-H tumors presented mutations in this gene sug-
gesting a crucial role for 2M in the metastatic process [47]. 
At the same time the lack of MHC class I expression could 
trigger a NK cell-mediated killing of these tumor cells, rep-
resenting another mechanism of tumor control [43]. 
  The prognostic significance of MMR deficiency has been 
evaluated also in correlation with the response to adjuvant 
chemotherapy. MMR defective cells have been shown to be 
more resistant to 5-fluorouracil (5-FU) activity than wild 
type MMR cells, indicating that MSI tumors may be less 
sensitive to some chemotherapeutics [48]. Moreover, when 
MMR deficiency is caused by MLH1 hypermethylation, de-
methylating its promoter region restores cell sensitivity to 5-
FU-induced DNA damage [49]. The majority of the studies 
performed so far are concordant in reporting that patients 
with MMR-deficient tumors do not benefit from adjuvant 
chemotherapy [50-52]. These data led to the conclusion that 
there are no scientific evidences justifying the treatment of 
LS patients with adjuvant chemotherapy protocols based on 
5-FU [53]. 
ASCERTAINMENT CRITERIA, DIAGNOSIS AND 
FOLLOW UP 
  Personal and family informations are crucial in identify-
ing patients with a higher risk of CRC. The first criteria pro-
posed to identify LS families were established during a 
meeting of the International Collaborative group on HNPCC 
held in Amsterdam in 1991 and then named Amsterdam cri-
teria I. However they fail to detect up to 50% of families 
with LS [54]. Few years later, the Amsterdam criteria II were 
revised to include the extra-colonic cancers that are integral 
part of the syndrome [55]. The Bethesda guidelines origi-
nally proposed in 1997 [56], and revised (RBG) in 2004 
[57], aimed to incorporate MSI and immunohistochemistry 
(IHC) testing to improve the identification of cases with de-
layed onset and/or weak family history. The presence of a 
young age at first cancer onset in association with a positive 
family history and/or multiple primary LS-related tumors has 
been shown effective in selecting the patients who should 
undergo MSI testing [12]. The presence, in LS-related tu-
mors, of TILs and of the specific histopathological features 
previously mentioned, are also useful for patient selection 
[58]. However, the ascertainment of cases based exclusively 
on family history may miss a substantial proportion of pa-
tients carrying germline mutations in MMR genes due to 
small nuclear families and incomplete anamnesis [59]. To 
avoid this recruitment bias, more recent approaches recom-
mended including all patients <50 years in presence of CRC 
or of any other LS spectrum tumor, even in absence of a 
cancer family history [12]. Because of their high sensitivity 
and specificity in identifying LS-related tumors, IHC and 
MSI have been proposed as large-scale first tier screening 
tests for all patients who develop a CRC [1]. However, the 
only direct confirmation of LS diagnosis is the identification 
of a causative mutation in one of the MMR genes. Indeed, 
although molecular screening of these genes is costly and 
time consuming it becomes cost-effective when supported by 
IHC and MSI-based selection. 
  The MSI phenotype is considered the most effective tool 
in identifying LS patients and represents a strong prognostic 
and predictive marker for patients’ clinical management. 
Considering that 90% of Lynch associated tumors are MSI-
H, mutation testing in presence of a positive MSI test in 
young cancer patients is recommended.  
  IHC to detect MLH1, MSH2, MSH6 and PMS2 expres-
sion in tumor tissue is routinely used by pathology laborato-
ries to identify a defective MMR system. While the complete 
loss of expression of MLH1 and MSH2 causes the biallelic 
inactivation of the corresponding MMR gene, the lack of 
PMS2 or MSH6 protein expression can also be caused by the 
instability of the heterodimeric complexes consequent to the 
loss of MLH1 and MSH2, respectively. In fact, when one of 
these two proteins is lost, the MutS and MutL heterodimers 
cannot be assembled leading to the rapid degradation of the 
corresponding partners, MSH6 and PMS2. In contrast, germ-
line mutations in MSH6 or PMS2 cause isolated loss of the 
encoded protein in the tumor tissue [60]. The sensitivity of 
IHC analysis (95%) is comparable to that of MSI analysis 
and indicates which MMR gene should undergo mutation 
search. Inaccurate sampling and heterogeneous staining rep-
resent major limits of IHC, requiring the supervision of an 
expert pathologist for a correct diagnosis [61]. Occasionally, 
cases presenting incomplete loss of the MLH1 protein ex-
pression have been reported in patients with a proven germ-
line missense mutation of unknown clinical significance 
[62]. These mutations may produce a non functional protein 
still able to be expressed at normal levels. In these cases, the 
diagnosis of LS should be supported by functional assays of 
the mutant MMR protein [63].  
  The young age at cancer onset and the relative high inci-
dence of CRC observed in Lynch mutation carriers argue for 
their tight surveillance. In a recent study, the survival rate at 
5 years in patients regularly screened by colonoscopy was 
nearly 98%, compared with 12% of those who declined sur-
veillance, and the CRC incidence decreased from 27% to 
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beginning of the surveillance at a younger age (20-25 years) 
are helpful in reducing CRC risk and death in mutation carri-
ers. The recently developed chromoscopic colonoscopy ap-
pears to improve the detection of suspicious lesions such as 
flat and pedunculated adenomas compared to standard 
colonoscopy [65]. Subtotal colectomy, followed by annual 
screening of the remaining rectal segment, is usually pro-
posed to patients as an alternative to lifetime colonoscopy. 
Prophylactic surgery is an option for patients with a low 
compliance for invasive screening procedures [39]. The risk 
for other LS-related cancers could be also substantially re-
duced by intensive surveillance and follow-up strategies 
[66]. The organ-specific surveillance includes transvaginal 
ultrasound for endometrial cancers, possibly combined with 
endometrial sampling, starting at the age of 30-35 years. 
Prophylactic hysterectomy and oophorectomy could be con-
sidered when childbearing is completed [67]. In case of fam-
ily history for gastric and small bowel tumors a periodic up-
per endoscopy is recommended. Finally, in families with 
ureter/renal pelvis cancer, patients should have annual ultra-
sound and urinalysis with cytological examination from age 
30 or at first evidence of hematuria [53]. 
GENOTYPE-PHENOTYPE CORRELATION IN 
LYNCH SYNDROME 
  Although tumor predisposition is inherited with an auto-
somal dominant pattern, Lynch syndrome is a complex dis-
ease characterized by genetic heterogeneity and an extreme 
variability in phenotypic manifestations. Mutations in the 
MSH2 and MLH1 genes account for up to 70% of defects 
identified in Lynch families, while mutations in MSH6 and 
PMS2 are identified in the remaining 14% and 15% [68]. 
Differences in cancer risk, depending on gender and the mu-
tated gene have been reported. The global risk associated 
with MSH6 and PMS2 mutations is substantially lower com-
pared to the risk conferred by mutations in MLH1 and 
MSH2 [69].  
  Individuals with MSH2 mutations have a higher cumula-
tive lifetime risk of developing primary extracolonic and 
cerebral tumors compared to MLH1 mutation carriers [70-
72]. Different functions in the MMR system of MSH2 and 
MLH1 might be responsible for the variation in cancer risk 
observed. However, not only the mutated MMR gene but 
also the specific phenotype observed in the families should 
be taken into consideration while deciding the surveillance 
protocol [73]. In recent years, several founder/recurrent mu-
tations in MMR genes have been identified which provide an 
important tool for population specific mutations [74]. The 
evaluation of a specific cancer risk attributable to these mu-
tations may be helpful for clinical follow-up and patients’ 
management. For instance, a mutation in the MLH1 gene 
associated with a lower risk of endometrial and extracolonic 
cancers has been identified in the Danish population [75] 
while an MLH1 founder mutation associated with an aggres-
sive phenotype and extracolonic manifestations has been 
described in Southern Italy [12]. Studies on the MSH2 
A636P founder mutation in Ashkenazi Jews have shown a 
higher risk of CRC and endometrial cancer associated with 
this variant and led to the proposal of adopting a specific 
surveillance protocol in the mutation carriers [76]. The well 
known recurrent mutation in the MSH2 gene localized at 
intron 5 splice site, c.942+3A>T, and resulting in skipping of 
exon 5 [77,78], apparently causes a different gender specific 
cancer risk. Specifically, the risk of CRC and death associ-
ated with this mutation is higher in male carriers compared 
to females that instead present a significantly higher risk of 
ovarian cancer [79,80]. 
  Patients harboring mutations in the MSH6 gene present a 
lower risk of CRC and a more advanced age at first tumor 
diagnosis [81,82]. It has been proposed that the presence of 
the MSH3 protein provides a partial compensation for the 
loss of MSH6 in the MMR functions [14]. In women carry-
ing MSH6 mutations, the risk for endometrial cancer is dou-
bled compared with that of MLH1 or MSH2 female mutation 
carriers [71]. Considering these features, for patients with a 
germline mutation in MSH6 a specific surveillance protocol 
has been proposed consisting of biennial colonoscopy start-
ing by the age of 30 years instead of 20-25 years, while pro-
phylactic hysterectomy should be considered from an age of 
45 years [83]. The phenotypic variability and the frequent 
association with a MSI-L classification may complicate the 
identification of MSH6 mutation carriers [84]. 
  PMS2 mutations have been identified in families meeting 
the RBG with tumors presenting isolated loss of PMS2 at 
IHC analysis [85]. The contribution of this gene to the LS 
pathogenesis has been overlooked until recent years for the 
difficulty to identify gene mutations due to the presence of 
pseudogenes. However, the use of PMS2-specific long range 
PCRs has increased the mutation detection rate [86,87]. The 
phenotypic consequence of PMS2 mutations seems to be 
highly variable, with weaker family history and older age of 
onset. The penetrance observed for PMS2 mutation carriers 
is lower compared with the one associated to mutations in 
other MMR genes but colorectal and endometrial cancer 
incidences are respectively 5 and 7-fold higher than in the 
general population [88].  
  Lynch syndrome also presents rare cases of biallelic mu-
tations [89]. Both homozygosity and compound heterozygos-
ity for MMR deficiency are not lethal while they cause early 
onset disease manifestations, which includes a neurofibro-
matosis-like phenotype (cafè au lait spots) often associated 
with leukemia or lymphoma, and cerebral and gastrointesti-
nal malignancies [90]. 
  Mutations in other genes of the MMR system, such as 
MLH3 and ExoI, have been rarely reported in association 
with familial CRC, but their association with LS is still de-
bated [91,92]. These two genes have been taken into consid-
eration since they are an integral part of MMR system but so 
far there are no compelling evidences of their role in LS 
pathogenesis. 
  An increasing number of LS cases caused by germline 
epigenetic inactivation of MLH1 has been reported [93-95]. 
These mutations, also referred as constitutional epimutations, 
have been identified in LS family with no mutations in 
MMR genes and early onset and/or multiple cancers [96,97]. 
A novel mechanism of MMR inactivation has been described 
in patients with IHC-negative MSH2 tumors, and tested 
negative in MSH2 mutational analysis. In these families 
germline deletions of the 3’ region of the EpCAM gene have 
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the EpCAM locus and deletions of this gene lead to MSH2 
inactivation by two different mechanisms: i) methylation of 
the CpG island at 3’ of EpCAM gene which causes constitu-
tional silencing of MSH2 [98], and ii) generation of an Ep-
CAM-hMSH2 fusion transcripts [16]. Patients with EpCAM 
deletions present a high risk of CRC, while endometrial can-
cer risk apparently depends on the extension of the deleted 
region [99].  
  So far, over 1500 mutations in four major MMR genes 
have been described [100]. The International Society for 
Gastrointestinal Hereditary Tumors (InSIGHT) has estab-
lished a database (www.insight-group.org) where all the 
identified variants and the results of functional and segrega-
tion studies eventually performed are listed [101]. The most 
common mutation type in the MSH2 gene is represented by 
large deletions (>30%) mediated by the presence of a cluster 
of Alu sequences [102]. Large rearrangements including 
deletions/duplications of single or multiple exons have been 
described also in MLH1 (5 %) [103-105].  
  The pathogenic role of mutations producing an unstable 
truncated protein is easily assessed since they cause lack of 
IHC staining in the tumor tissue. More difficult is the inter-
pretation of the pathogenicity of missense mutations that 
account for 31% of MLH1 and 17% of MSH2 mutations 
[106]. Many different methods have been developed to 
evaluate the consequences on the protein function of these 
“Variants of Uncertain Significance” (VUS). In these cases, 
the first step in assessing their pathogenicity is to analyze the 
co-segregation of the variant within a family and the deter-
mination of its frequency in control populations. A second 
step is usually represented by the evaluation of the evolu-
tionary conservation of these variants and/or of the region 
where they are localized. Essential domains for MMR pro-
teins activity are the regions interacting with other MMR 
proteins or those with catalytic activity. In fact, missense 
mutations may directly affect protein function but can also 
interfere with protein stability, interactions or localization. 
Understanding how a single amino acid change contributes 
to disease pathogenesis is important for the management of 
mutation carriers harboring that particular variant. Both in 
silico and experimental procedures have been used in order 
to assess the pathogenicity of VUS [107], and a three-step 
model has been recently proposed [108,109]. Another bioin-
formatic algorithm based on evolutionary conserved se-
quences alignments, called Multivariate Analysis of Protein 
Polymorphisms-Mismatch Repair (MAPP-MMR), has been 
also developed to help in the pathogenetic classification of 
MMR-VUS [110]. Although functional studies are important 
to clarify the role of VUS [111], the loss of the repairing 
proficiency of the mutated protein by in vivo or in vitro as-
says is not easy to demonstrate [112].  
  The pathogenic role of some variants may also depend 
upon genetic background, environmental influences, life 
style, and modifier genes. All these factors have been hy-
pothesized to explain the unanswered question of the high 
variability in cancer risk observed in LS patients, even 
among carriers harboring the same mutation. The under-
standing of the contribution of these factors, including low-
risk alleles and modifier genes, in LS patients it is important 
to plan surveillance protocols tailored to the individual risk 
of cancer development. The majority of modifier genes 
investigated so far, have been selected on the basis of their 
putative biological role in cancer initiation or progression. 
This strategy has led to the identification of candidates such 
as the polymorphic CA repeat within the IGF1 promoter 
[113], a SNP within the xenobiotic metabolizing enzyme 
gene CYP1A1 [114] and many other candidate modifier 
genes that may profile the clinical presentation in MLH1 and 
MSH2 mutation carriers [115-118]. 
  In few studies the quantitative evaluation of allele-
specific expression of MMR genes in mutation carriers has 
been performed [119,120]. The allelic expression imbalance 
(AEI) is an additional factor that could contribute to variabil-
ity in the disease phenotype [120]. Differential allelic ex-
pression can be influenced by sequence polymorphisms in 
regulatory regions as well as by the presence of mutations 
able to modify the level of gene expression. Analysis of AEI 
in NMD-insensitive mutation carriers revealed that MLH1 
expression is influenced by two SNPs acting in cis, even if 
these influences are relatively small compared to variations 
in expression level caused by the presence of pathological 
mutations [121]. 
  Recently, the introduction of genome-wide association 
studies (GWAS) revealed several SNPs that appear to influ-
ence CRC onset. Wijnen et al. [122] have identified two loci 
on 8q23.3 and 11q23.1 causing an increased risk of CRC in 
LS mutation carriers that were significantly associated with 
the number of risk alleles and an influence stronger in female 
carriers than in males. However, the role of these variants is 
still debated. A recent study on the French population did not 
find any association of these two loci with an increased CRC 
risk nor a sex specific risk [123], while a study on Australian 
and Polish populations has been able to replicate the associa-
tion only in MLH1 mutation carriers [124]. The different 
results with previous studies may be due to genetic hetero-
geneity and different MMR mutations between analyzed 
populations and underline the necessity to increase the power 
of these studies to provide a definitive answer.  
LYNCH SYNDROME AND ANTICIPATION  
  Genetic anticipation by Strachan and Read’s definition 
[125] is “a phenomenon in which the age of onset of a disor-
der is reduced and/or the severity of the phenotype is in-
creased in successive generation”. For long time, geneticists 
have been skeptical on the real existence of the phenomenon. 
Clinical anticipation in diseases onset has been reported 
since 19
th century but it was for long time considered an as-
certainment bias until the identification of the trinucleotide 
expansion mechanism in a group of inherited neuromuscular 
disorders. This mechanism represents the first molecular 
model able to explain the phenomenon of anticipation [126].  
  Today, genetic anticipation is a clinical feature character-
izing a consistent number of neurodegenerative disorders 
known as dynamic diseases, which include, among the oth-
ers, myotonic dystrophy, X-linked mental retardation, 
Huntington’s chorea, and Friedreich ataxia. The well-known 
molecular mechanism behind the progressively earlier onset 
and the increased severity observed in affected families is the 
generational expansion of trinucleotide repeats during suc-
cessive meiosis. A sex-specific inheritance pattern has been 456    Current Genomics, 2011, Vol. 12, No. 7  Bozzao et al. 
proposed for the juvenile forms of these diseases because the 
triplets’ expansion occurs most frequently during male 
gametogenesis [127]. Evidence for genetic anticipation has 
been described also in cancer genetic syndromes like breast 
cancer, pancreatic cancer, ovarian cancer, leukemia, lym-
phoma and melanoma [128-133]. 
  The progressive decrease of age at diagnosis of CRC in 
successive generation has been reported since the first de-
scription of Lynch syndrome in 1925 by Alfred Whartin 
[134]. Over the years many studies investigated on the pos-
sibility of anticipation in this syndrome (see Table 1). 
  Menko and te Meerman reported the first clinical obser-
vation of anticipation in LS in 1993, but their data derived 
from families with uncertain mutation status and no statisti-
cal analysis was performed [135].  
 Vasen  et al. [136] in a clinical study investigated the age 
of onset of CRC in 49 families with at least three relatives 
affected in two successive generations. In 41 families satis-
fying this minimum criterion for LS, a progressively earlier 
age of diagnosis of CRC in successive generations was ob-
served. The remaining eight families presented later age of 
onset and the absence of extracolonic cancers frequently 
associated with LS. No molecular information was available 
for the families included in this study, and the author did not 
exclude the possibility of an ascertainment bias.  
  In 1996, Rodriguez-Bigas et al. analyzed 40 families 
fulfilling LS criteria and confirmed the presence of a genera-
tional anticipation in the disease onset [137].  
  Fifty-one Lynch families selected according to the 
Amsterdam Criteria were analyzed in a statistical study by 
Voskuil et al. [138] who concluded that the earlier age of 
onset in successive generation does not appear to be a bio-
logical event, but reflects a secular time trend in cancer oc-
currence in the families included in the study. 
  The first study arguing against the existence of anticipa-
tion in familial colorectal cancer of unknown causes was 
Table 1.  Anticipation Studies in Lynch Syndrome 
Author 
[Refer-
ence] 
No. of ana-
lyzed patients 
(No. of as-
ymptomatic 
carriers) 
No. of ana-
lyzed fami-
lies (No. 
with identi-
fied muta-
tion) 
No. of 
Ana-
lyzed 
PCPs 
Average 
anticipa-
tion in 
years  
No. of fami-
lies with 
MMR genes 
mutations  
Median age at 
onset according 
to mutated gene 
Average antici-
pation in years 
according to the 
mutated gene 
Statistical test used 
Vasen 
[126] 
194 (0)  41 (0)  ND 
8.5 yrs 
** 
ND ND  ND  Paired  t-test 
Rodriguez-
Bigas [127] 
301 (17)  40 (0)  ND 
YES 
(NA) 
ND ND  ND  NA 
Voskuil 
[128] 
1186 (956)  51 (12)  ND  NO  NA  ND  ND 
Cox proportional 
hazards regression 
modelling 
Tsai [129]  NA  38 (7)  67  NO 
4 MLH1 
3 MSH2 
ND 
ND 
ND 
ND 
Gehan’s generalized 
Wilcoxon test 
Westphalen 
[130] 
83 (0)  21 (21)  55  8 yrs ** 
15 MLH1 
6 MSH2 
42.5 (18-62) 
MLH1 
46 (29-60) MSH2 
 11 yrs ** 
2 yrs NS 
Wilcoxon matched 
pairs signed-ranks 
test 
Stella [131]  NA  4 (4)  24  12 yrs **  4 MSH2  -  - 
Wilcoxon matched 
pairs signed-ranks 
test 
Nilbert 
[132] 
407 (0) 
 
92 (92)  290 
9.8 yrs 
**/5.5 
yrs ** 
32 MLH1 
43 MSH2 
17 MSH6 
46.7 (5-82) 
MLH1 
44.4 (14-86) 
MSH2 
52.9 (18-83) 
MSH6 
10.10 yrs** / 
5.42 yrs * MLH1 
7.58 yrs ** / 5.11 
yrs ** MSH2 
9.75 yrs **/ 6.43 
yrs * MSH6 
Paired t-test/Huang 
and Vieland’s bi-
variate model 
Larsen 
[134] 
824 (0) 
 
125 (125)  NA  3 yrs ** 
44 MLH1 
59 MSH2 
22 MSH6 
ND 
ND 
ND 
2.86 yrs # MLH1 
2.49 yrs # MSH2 
5.13 yrs # MSH6 
Parametric model 
ND= Not Done; NA=Not Available; NS= Not Significant. 
* p<0.05, **p<0.001, # p value not applicable. Anticipation in Lynch Syndrome  Current Genomics, 2011, Vol. 12, No. 7    457 
published by Tsai et al. [139]. In this study 475 parent-child 
pairs (PCPs) with familial colorectal cancer were analyzed 
using statistical approach to correct for selection biases and 
cohort effects (many statistical tests were used including 
Gehan’s generalized Wilcoxon test, unpaired t-test, paired t-
test, Pearson’s correlation coefficient, ANOVA). The 
authors found no evidence for an effect of parental gender on 
age at diagnosis in offspring, neither a secular trend toward 
younger onset of cancer. Tsai concluded that the clinical 
evidences of anticipation in LS previously reported probably 
reflected a birth cohort bias of ascertainment. MMR gene 
mutations status was known for only 14 of the 67 PCPs that 
met criteria for LS subgroup in this study. No difference in 
age at diagnosis between generations was observed in these 
families. Noteworthy, the mean age of parents and offspring 
was a decade younger in sporadic patients than in the LS 
subsample without identified mutations and the author could 
not exclude an association between MMR gene mutation and 
a very young onset of cancer. 
  The first evidence for genetic anticipation described pre-
sented some limitations: the limited power of statistical tests 
applied, the missing or incomplete molecular characteriza-
tion of patients, and the different time windows analyzed. As 
the molecular-testing of Lynch patients became routinely 
performed most of the published studies reported the pres-
ence of genetic anticipation in the Lynch families analyzed. 
 Westphalen  et al. [140] published a study on 55 affected 
parent-child pairs from 21 Swiss families with germline mu-
tations in MLH1 (15) and MHS2 (6) genes. After the exclu-
sion of a birth cohort effect, they observed 8 years anticipa-
tion, on average, in the age at tumor diagnosis in children 
compared with their parents. In particular, mutations in 
MLH1 were significantly associated with a more pronounced 
anticipation effect compared with MSH2 mutations, though 
this latter finding could have been due to the small sample 
size investigated. Furthermore, genetic anticipation appeared 
to be more evident when the mutation was paternally inher-
ited. 
  In 2007 Stella et al. [141] first reported evidence of an-
ticipation effects also in Lynch families segregating MSH2 
mutations. The authors analyzed 24 affected parent-child 
pairs from four families with deletions in MSH2 and ob-
served a median anticipation effect of 12 years. The authors 
found no indication of a birth cohort effect. It was not possi-
ble to evaluate the effect of the gender of the transmitting 
parent since only four of the PCP’s involved maternal trans-
mission. In this work, PCPs were more numerous than the 
MSH2 PCPs analyzed by Westphalen (24 vs 14) and more 
homogeneous in terms of mutation type. Moreover, the 
analysis was not limited to PCPs in which both parents and 
offsprings developed CRCs including pairs where either the 
parents or the children were asymptomatic. MSH2 mutations 
are more likely to be associated with extracolonic tumors 
and nine of the 24 PCPs presented a tumor of this type. 
However, a significant anticipation also emerged restricting 
the analysis to the 14 PCPs in which both the members had 
developed CRCs as the first diagnosed cancer. It seems un-
likely that the observed anticipation was significantly related 
to changes in surveillance policies because of the limited 
time distribution of patients. Still, it is possible that other 
genetic or environmental factors could play a role in the dif-
ferences in age at cancer diagnosis of patients, although the 
influence of environmental factors is difficult to assess con-
sidering the variety of organs involved in Lynch syndrome.  
  In 2008 a large Danish study on 290 parent-child Lynch 
pairs was published by Nilbert et al. showing a significant 
anticipation effect [142]. In this report, the children group 
developed a Lynch syndrome-associated cancer 9.8 years 
earlier, on average, compared to their relatives. They also 
analyzed different birth cohorts, all demonstrating anticipa-
tion including a 7.2 years earlier tumor development in the 
oldest cohort. To avoid biases linked to the variable follow-
up length in different generations and to the presence of 
shared genetic and/or environmental factors the authors used 
a statistical method developed by Huang and Vieland [143]. 
Taking into consideration the variable length of the follow-
up they were still able to demonstrate an anticipation effect 
of 5.5 years on average. Thus, two alternative statistical 
methods used in this work showed comparable results and 
the anticipation effect remained even when analyzing differ-
ent birth cohorts, different parent-of-origin of mutation, dif-
ferent MMR gene mutated, and also after the exclusion of 
cancers developed during the follow up period. In the fol-
lowing year, the same authors [144] developed a parametric 
statistical model to test anticipation that was applied to a 
larger version (824 individuals from 125 families) of the 
Danish Lynch syndrome cohort they analyzed in their previ-
ous work. This model allowed the analysis of right-censored 
data, considered several generations and included unaffected 
family members. The inclusion of covariates is a substantial 
improvement and facilitates subgroup comparison and the 
analysis of possible confounders. A significant effect from 
anticipation was still evident in the studied cohort using this 
new statistical model. 
  A review of the statistical methods used for testing ge-
netic anticipation has been published in 2010 by Boonstra et 
al. [145]. The authors applied the most common statistical 
tests to the Danish HNPCC-register and all the tests con-
firmed the presence of genetic anticipation in Lynch syn-
drome families.  
  In summary, with the only exception of the study pub-
lished by Tsai et al. [139], all the recent literature has re-
ported evidences in favor of the presence of genetic anticipa-
tion in Lynch syndrome. The clinical observation of antici-
pation in LS families and the statistical analyses performed 
in different studies do not necessarily demonstrate the bio-
logical existence of this phenomenon. Until a molecular 
mechanism capable of explaining the genetic anticipation in 
LS will not be found, it’s not possible to rule out that the 
observed effects can be due to sampling errors or to the ge-
netic and/or environmental common background of families.  
MOLECULAR BASIS OF ANTICIPATION IN LYNCH 
SYNDROME 
  Similarly with the molecular mechanisms responsible for 
anticipation in dynamic diseases, mutations in MMR genes 
have been hypothesized to lead to the same type of genera-
tional instability in repetitive sequences of DNA and that this 
could represent the biological basis of genetic anticipation in 
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  In 1994, Shibata et al. [146] were the first to suggest that 
the younger onset of cancer observed in consecutive genera-
tions of Lynch families could be explained by the accumula-
tion of mismatch repair slippage events due to the dimin-
ished DNA mismatch repair proficiency. Few years later, the 
same group using a mathematical model hypothesized that 
the number of mutations accumulated in a tumor was de-
pendent on the mutation rate and the number of cell division 
[147]. 
  The first evidence that mutations in microsatellite loci are 
present also in normal human tissue dates back to 2001 
[148]. However, the normal tissue analyzed in this study 
derived from a single patient with homozygous deficiency of 
MLH1.  
  Two different works published in 2005 have demon-
strated the presence of low level of microsatellite instability 
in the peripheral blood lymphocytes (PBLs) of Lynch carri-
ers long before tumor diagnosis [149,150]. Coolbaugh-
Murphy et al. [150] observed an age-dependent increase of 
the instability in carriers PBLs compared with normal con-
trols. In contrast, the level of MSI observed in PBLs DNA of 
patients with sporadic, MSI-H CRCs did not show any in-
crease when compared with age-matched controls. The 
authors concluded that MSI is not due to circulating cells 
from MSI-H tumors.  
  It is possible that germline mutations can already impair 
MMR proficiency prior to loss of heterozygosity partly con-
tributing to early-onset cancers. The mutation carriers would 
carry this milder impairment since birth, slowly accumulat-
ing alterations in any replicating cell type until they reach 
levels associated with an appreciably increased cancer risk 
only later in life.  
  If this is the case, the mutational load would be also pre-
sent in carriers’ germ cells during the reproductive years 
leading to the transmission of an overloaded gamete to the 
next generations. As a consequence, the offspring would 
inherit a more pronounced risk of cancer development. The 
increase in the accumulated mutation burden in successive 
generations would determine a progressive earlier cancer 
onset until the mutation levels will preclude further transmis-
sion (e.g. due to childhood or intrauterine death or even ab-
sent gametogenesis). This hypothesis is supported by the 
evidence that when anticipation has been observed in inher-
ited cancers, it is often limited to three consecutive genera-
tions [128]. Stella et al. [141] recently described an LS fam-
ily where a female infant died of a ureter cancer at the age of 
12 months. This case might be the result of the transmission 
of a particularly heavy mutational load, considered that the 
mutation was paternally inherited by a subject diagnosed 
with CRC at age 34. 
  So far only one study has investigated the association of 
MMR haploinsufficiency with a higher frequency of mutant 
microsatellite sequences in phenotypically normal cells 
[151]. In this study, a highly specialized and labor-intensive 
technique has been used to detect mutant microsatellite 
fragments in PBLs DNA that would be otherwise obscured 
by progenitor alleles when using traditional PCR-based 
genotyping. In all the seven patients analyzed in the study, 
there was a significantly higher frequency of mutant alleles 
for all the three loci tested compared to age-matched spo-
radic CRC patients and normal controls. The authors con-
cluded that their findings might represent the first molecular 
mechanism able to explain anticipation effects in LS. The 
low levels of genetic instability observed in normal cells 
from MMR mutation carriers, if present also in the germline, 
would cause mutations accumulation and transmission of 
mutant alleles to the offspring at a significantly higher fre-
quency than in non-carrier individuals.  
  Considering the large number of repeat-containing genes 
that have been linked to the pathogenesis of these tumors, 
differences in the mutation frequency at these target loci 
would be identified in the offspring germline DNA only by 
massive screening approaches. As the development of a can-
cer requires multiple mutation steps [152], any single trans-
mitted mutation would spare few years in this cascade, lead-
ing to the observed genetic anticipation in LS.  
  Future investigations with more sensitive methods of 
MSI quantification in large series of Lynch carriers should 
be able to proof this hypothesis.  
THE ROLE OF TELOMERE LENGTH IN ANTICI-
PATION 
  Telomere length attrition has been proposed as a novel 
mechanism of anticipation in different inherited diseases 
such as dyskeratosis congenita (DKC) [153] and Li-
Fraumeni syndrome [154, 155]. In DKC, the telomerase hap-
loinsufficiency, caused by mutations in the hTERC gene, 
which encodes for its catalytic subunit, causes a progressive 
telomere shortening in successive generations with an in-
creased predisposition to malignancy associated to the inher-
ited telomere length [156]. DKC represents a unique exam-
ple of a direct interaction of the mutated gene with telomere 
length maintenance mechanisms.  
  In Li-Fraumeni syndrome patients, carriers of germline 
mutations in the TP53 gene have shown an accelerated attri-
tion of telomere length compared with both normal controls 
[157] and asymptomatic carriers [155]. Since p53 directly 
binds to the telomeric t-loop junctions and controls the cellu-
lar response to DNA damage, mutations in TP53 would al-
low cells to escape apoptosis and proliferate even in presence 
of critically short telomeres thus leading to a gradual herita-
ble telomere shortening. Shorter telomeres in the germline of 
mutation carriers and their transmission to successive gen-
erations, combined with a faster lifetime attrition, may cause 
carriers to decrease telomere length under a critical threshold 
earlier in life triggering anticipated cancer onset [155]. A 
similar explanation has been proposed for patients with fa-
milial papillary thyroid cancer (FPTC) in which a shorter 
telomere length in PBLs has been observed compared with 
sporadic cases [158]. 
  Both genetic anticipation and telomeres shorter than in 
normal age-matched controls have been observed also in 
familial breast cancer [159,160]. 
 Bozzao  et al. [161] recently reported the evaluation of 
the telomere length in patients with Lynch syndrome. The 
authors analyzed 38 MLH1 and 36 MSH2 mutation carriers 
from 21 Lynch families: 43 presented with a cancer of the 
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mean telomere length in Lynch carriers did not differ from 
controls and declined with age in a similar manner. Con-
versely, affected patients demonstrated accelerated telomere 
attrition compared with normal individuals, whereas asymp-
tomatic carriers had a slower decline with age. 
  MSH2 mutation carriers had significantly shortened te-
lomeres compared with controls, whereas, in MLH1 carriers, 
the correlation between telomere length and age was loose 
and not significant. Furthermore, telomere attrition was cor-
related significantly with the age at onset in MSH2 carriers. 
In fact, patients who developed tumor relatively early had 
significantly longer telomeres than those who became symp-
tomatic later in life. In contrast, MLH1 patients with advanc-
ing age of onset presented longer telomeres and increasing 
telomere length. These findings have been confirmed by a 
very recent study showing that MSH2 down-regulation in 
normal human fibroblasts induces an accelerated telomere 
shortening rate [162]. In MSH2
-/-Terc
-/- mice, MSH2 defi-
ciency abolished the anti-oncogenic effects of short te-
lomeres in a p21/p53-dependent manner [163]. Haploinsuffi-
ciency for MSH2 gene may induce tolerance to very short 
telomeres, leading to faster telomere attrition, while a reduc-
tion in the MLH1 dosage could trigger homologous recom-
bination-dependent ALT (Alternative Lengthening of Te-
lomeres), causing telomere elongation. In fact, in human 
cells down-regulation of MLH1, but not of MSH2, lead to 
enhanced homologous recombination (HR), which is com-
monly believed to play a crucial role in ALT [164,165]. This 
model would explain the lack of a correlation between te-
lomere length and age, which was observed only in MLH1 
mutation carriers. The authors speculated that haploinsuffi-
ciency in somatic and germ cells of Lynch patients may 
slowly exert different effects on the telomere length inherited 
at birth, according to the presence of either MLH1 or MSH2 
mutations. Thus, MSH2 and MLH1 genes may contribute 
differently to the balance between telomere shortening and 
lengthening activities according to the mechanisms depicted 
in Fig. (1). 
CONCLUSIONS 
  Mounting evidences show that anticipation is commonly 
associated with LS. The earlier onset of cancer in successive 
generations raises the issue of a stricter surveillance proto-
cols in younger generations. It is likely that the telomere 
length may represent one of the factors that influences cancer 
onset and may also contribute to anticipation effects. How-
ever, other genetic and environmental factors could act in 
modifying cancer risk in Lynch syndrome patients. The iden-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A diagram illustrating telomere dynamics in MMR mutation carriers. MSH2 deficiency leads to increased tolerance for shorter 
telomeres and telomere instability that accelerate telomere shortening. In a mouse Terc
-/- model this enhanced tolerance has been demon-
strated to be p21/p53 dependent. In contrast, MLH1 deficiency causes an increase in homologous recombination (HR) which is considered 
one of the principle mechanisms for the alternative lengthening of telomeres (ALT) thus opposing to telomere shortening. 460    Current Genomics, 2011, Vol. 12, No. 7  Bozzao et al. 
tification of these additional factors may lead in a near future 
to a more precise definition of individual cancer risk and 
tailored clinical surveillance. 
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